Omecamtiv Mecarbil + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Heart Failure With Reduced Ejection Fraction

Conditions

Heart Failure With Reduced Ejection Fraction

Trial Timeline

Apr 9, 2019 → Jan 6, 2022

NCT ID

NCT03759392

About Omecamtiv Mecarbil + Placebo

Omecamtiv Mecarbil + Placebo is a phase 3 stage product being developed by Cytokinetics for Heart Failure With Reduced Ejection Fraction. The current trial status is completed. This product is registered under clinical trial identifier NCT03759392. Target conditions include Heart Failure With Reduced Ejection Fraction.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03759392	Phase 3	Completed	Apr 9, 2019	Jan 6, 2022	Heart Failure With Reduced Ejection Fraction
NCT02601001	Phase 1	Completed	Nov 13, 2015	Jan 6, 2016	Healthy Volunteer

Competing Products

20 competing products in Heart Failure With Reduced Ejection Fraction

See all competitors

Product	Company	Stage	Hype Score
IV diuretic	Nuwellis	Pre-clinical	15
IV Loop Diuretics	Nuwellis	Pre-clinical	15
Stepped pharmacologic care	Nuwellis	Phase 3	69
IV Loop Diuretics (LD)	Nuwellis	Pre-clinical	15
TRV120027 + Normal Saline	Trevena	Phase 1	25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	44
TRV120027 + Placebo	Trevena	Phase 1/2	33
Ilofotase alfa + Placebo	AM-Pharma	Phase 2	44
INXN-4001	Precigen	Phase 1	28
LY3461767 + Placebo	Eli Lilly	Phase 1	33
SGLT2i, beta blocker, ARNI, MRA, MTD	Eli Lilly	Approved	85
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	52
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks	Daiichi Sankyo	Approved	85
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil	Daiichi Sankyo	Phase 3	77
Olmesartan	Daiichi Sankyo	Phase 3	77
Carperitide + Placebo	Daiichi Sankyo	Phase 2	52
Edoxaban	Daiichi Sankyo	Pre-clinical	23
Regadenoson	Astellas Pharma	Phase 1	33
Advagraf + Prograf	Astellas Pharma	Phase 2	52
FK506E	Astellas Pharma	Phase 3	77

Other Products from Cytokinetics

Tirasemtiv + Placebo tabletsPhase 3

Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) + Placebo to match aficamtenPhase 3

Omecamtiv Mecarbil (OM) + PlaceboPhase 3

Omecamtiv mecarbilPhase 3

ReldesemtivPhase 3